Alnylam Pharmaceuticals (ALNY) stock is soaring 13.23% in Thursday's pre-market trading session following the release of its stellar second-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analysts' expectations, demonstrating robust growth across key metrics and prompting an increase in its full-year guidance.

The company reported total revenues of $773.7 million for Q2 2025, marking a 17% increase compared to the same period last year. Notably, total net product revenues reached $672 million, representing a substantial 64% year-over-year growth. This surge was primarily driven by the company's TTR franchise, which generated revenues of $544 million, up 77% from the previous year. Alnylam's non-GAAP earnings per share of $0.34 significantly outperformed the IBES estimate of -$0.77, despite a widening GAAP net loss per share of $0.51.

Buoyed by its strong performance, Alnylam has raised its 2025 guidance, projecting total net product revenues between $2.65 billion and $2.8 billion, representing a 27% increase at the midpoint. The company's optimistic outlook is further supported by recent regulatory approvals for its ATTR-CM treatment in several markets, including the European Union, Brazil, the United Kingdom, and Japan. Additionally, Alnylam has initiated new clinical trials, including the TRITON-CM Phase 3 trial of Nucresiran, signaling continued growth potential. This combination of strong financial results, raised guidance, and positive operational developments has fueled investor confidence, contributing to the stock's significant pre-market rally.